Loading…
← CockpitCompetitor Analysis › 145020.KS Hugel, Inc.Open in the cockpit ↗

Hugel, Inc.145020.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.

≈ Korea's Allergan/Botox equivalentMomentum strong 60
Mkt cap
$1.69B
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$7.97M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
+17.5 pp
WACC 5.6%
Hurdle
-27 pp
Req g minus delivered
Next earnings
91 days
17 Feb 2027
Close · KRW₩198,500
1D+3.1%
1W+1.5%
1M+7.8%
3M-22.5%
6M-30.5%
YTD-13.9%
1Y-8.7%
ATR %4.6%
52w lowhigh35.7% off high

What Hugel does

Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.

Sells its toxin and fillers to clinics, relying on distributors in each export market and on regulatory approvals country by country. Its toxin, also sold as Letybo, won US FDA approval in 2024, opening the largest aesthetics market. Exports are a large part of sales.

In one line: Korea's Allergan/Botox equivalent.

Products and services

  • Botulax (botulinum toxin)
  • Dermal fillers
  • Skincare/cosmetics

Customers

  • Dermatology/aesthetic clinics (Korea, China, globa

Where it sits in the supply chain

  • Aesthetics/biopharma
  • Botulinum toxin & dermal fillers
  • Global aesthetic-injectable export

What could go right

  • China/global aesthetic market expansion
  • New country regulatory approvals

What could go wrong

  • Toxin-market pricing competition
  • IP/litigation disputes with rivals

Moat: narrow (regulatory licence, brand). Regulatory-approved toxin strains and manufacturing scale are hard and costly to replicate.

Headquarters: Chuncheon, South Korea · Founded: 2001 · Employees: 629

Named competitors

Hugel at a glance

Size Hugel (145020.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.69B, the 158th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩198,500 on 18 Nov 2026.

Performance Over six months the shares fell 30.5%, against 0.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 16.6% over the last twelve months (peer median +25.5%); the operating margin is 38.1% (peer median -0.2%).

Valuation It trades at 18.1× forward earnings against a peer median of 39.7× (3rd cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 17.5 points above its cost of capital (5.6% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 101145020.KS 70
Six months, rebased to 100: Hugel against the median of its 20 peers (local-currency closes).

Hugel financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩471B₩425B₩373B₩320B₩282B
Revenue growth—+14%+17%+13%—
Gross profit₩354B₩323B₩278B₩238B₩211B
EBITDA₩202B₩220B₩181B₩132B₩115B
Net income₩125B₩141B₩136B₩93.1B₩60.7B
Free cash flow₩149B₩137B₩137B₩94.0B₩47.8B
Capital expenditure₩69.2B₩29.5B₩33.3B₩40.6B₩45.0B
Total debt₩25.7B₩29.1B₩37.6B₩90.5B₩101B

Quarterly statements and history in the cockpit →

Hugel competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%STOK600226RXRXANIPALVO6882226949688046PPGNZBIOCOAGVIRVERANRIXTRAXPGENKLRA145020.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Hugel is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×50×100×600226ANIPALVO688222688046PPGN300601PGEN145020.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hugel is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%ANIP688222688046300601145020.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hugel is the large dot.

Hugel competitors and peer comparison

Head to head with its named competitors (145020.KS vs 086900.KS vs 069620.KS vs ABBV)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hugel 145020.KS$1.69B-30%+17%38%18.1×-12.1%
Medy-Tox 086900.KS$350M-36%+3%10%18.1×4.7%
Daewoong Pharm 069620.KS$856M-33%+9%12%9.0×n/a
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Ipsen IPN.PA$14.8B+1%+14%30%10.8×-6.7%

How Hugel compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hugel against its 20 peers (data as of 18 Nov 2026)
Measure145020.KSPeer medianRank in peer set
1-month return+7.8%-7.8%4th highest of 20
6-month return-30.5%0.0%3rd lowest of 20
Distance from 52-week high-35.7%-36.1%10th highest of 21
Revenue growth (TTM)+16.6%+25.5%7th lowest of 17
Operating margin38.1%-0.2%2nd highest of 18
Forward P/E18.1×39.7×3rd cheapest of 9
Growth the price implies (Req g, 7 yrs)-12.1%27.8%least demanding of 5
Growth delivered (Del g)+15.0%+20.8%2nd lowest of 5
Hurdle (Req g minus delivered)-27.1 pp+12.3 pp2nd least demanding of 5
ROIC minus cost of capital+17.5 pp-4.4 pphighest of 13
EV / EBITDA8.5×19.5×3rd cheapest of 6
Net debt / EBITDA-2.8×1.0×2nd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%n/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%105.5×22.7%+3.4%
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a

Questions

Who are Hugel's main competitors?
Named competitors: Medytox (086900.KS), Daewoong Pharmaceutical (069620.KS), AbbVie (Botox/Allergan) (ABBV), Ipsen (Dysport) (IPN.PA). The cockpit's measured peer set (industry) also includes Stoke Therapeutics (STOK), Zhejiang Hengtong (600226.SS), Recursion Pharmaceuticals (RXRX), ANI Pharmaceuticals (ANIP), Alvotech (ALVO), Hitgen (688222.SS).
Is Hugel expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 39.7×, 3rd cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has Hugel stock performed?
Over six months to 18 Nov 2026 the shares returned -30.5% against 0.0% for the median peer; over one year -8.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.